Database : MEDLINE
Search on : Arthralgia [Words]
References found : 11447 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1145 go to page                         

  1 / 11447 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29476812
[Au] Autor:de Melo AB; de Souza WM; Acrani GO; Carvalho VL; Romeiro MF; Tolardo AL; da Silva SP; Cardoso JF; de Oliveira Chiang J; da Silva Gonçalves Vianez JL; do Socorro da Silva Azevedo R; Figueiredo LTM; da Costa Vasconcelos PF; Nunes MRT; de Almeida Medeiros DB
[Ad] Address:Department of Arbovirology and Hemorrhagic Fevers, Evandro Chagas Institute, Ministry of Health, Ananindeua, Pará, Brazil.
[Ti] Title:Genomic characterization and evolution of Tacaiuma orthobunyavirus (Peribunyaviridae family) isolated in Brazil.
[So] Source:Infect Genet Evol;60:71-76, 2018 Feb 21.
[Is] ISSN:1567-7257
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Tacaiuma virus (TCMV) is antigenically characterized as a member of the Anopheles A complex in the Orthobunyavirus genus, Peribunyaviridae family (Bunyavirales order). Clinically, the TCMV infection is characterized by acute febrile illness with myalgia and arthralgia lasting three to five days. However, the genomic and evolutionary aspect of this virus has not been elucidated. In this study, we described the complete coding sequences of three segments of two TCMV strains isolated in Brazil and three complete coding sequences of the small segment of three TCMV strains. All the strains sequenced in this study showed the typical genomic organization of orthobunyaviruses that infect vertebrates, except for the absence of the open reading frame that encodes the well-described non-structural small protein. This study presents the genomic and evolutionary characterization of TCMV strains and would be helpful for diagnostic purposes and epidemiology.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29188284
[Au] Autor:Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
[Ad] Address:Memorial Sloan Kettering Cancer Center, New York, New York.
[Ti] Title:Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
[So] Source:JAMA Oncol;4(3):384-388, 2018 Mar 01.
[Is] ISSN:2374-2445
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Importance: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy and safety of prolonged vemurafenib use in these patients are not defined. Here we analyze the final efficacy and safety data for vemurafenib in patients with ECD and LCH enrolled in the VE-BASKET study. Objective: To determine the efficacy and safety of vemurafenib in adults with ECD or LCH enrolled in the VE-BASKET study. Design, Setting, and Participants: The VE-BASKET study was an open-label, nonrandomized, multicohort study for patients with nonmelanoma cancers harboring the BRAF V600 mutation. Patients with BRAF V600-mutant ECD or LCH were enrolled in an "other solid tumor" cohort of the VE-BASKET study, and they were enrolled in the present study. Interventions: Patients received vemurafenib, 960 mg, twice daily continuously until disease progression, study withdrawal, or occurrence of intolerable adverse effects. Main Outcomes and Measures: The primary end point was confirmed objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Secondary end points included progression-free survival (PFS), overall survival (OS), metabolic response by modified positron-emission tomography (PET) Response Criteria in Solid Tumors (PERCIST) using 18F-fluorodeoxyglucose (FDG)-PET/computed tomography (CT), and safety. Results: A total of 26 patients from the VE-BASKET trial (22 with ECD, 4 with LCH) were included in the present study (14 women and 12 men; median age, 61 years; age range, 51-74 years). The confirmed ORR was 61.5% (95% CI, 40.6%-79.8%) in the overall cohort and 54.5% (95% CI, 32.2%-75.6%) in patients with ECD. All evaluable patients achieved stable disease or better. The median PFS and OS had not been reached in the overall cohort at study closure despite a median follow-up of 28.8 months; 2-year PFS was 86% (95% CI, 72%-100%), and 2-year OS was 96% (95% CI, 87%-100%). All 15 patients evaluated by FDG-PET/CT achieved a metabolic response, including 12 patients (80%) with a complete metabolic response. The most common adverse events (AEs) in the overall cohort included arthralgia, maculopapular rash, fatigue, alopecia, prolonged QT interval, skin papilloma, and hyperkeratosis. Hypertension and dermatologic AEs occurred at higher rates than those reported in metastatic melanoma. Conclusions and Relevance: In this study, vemurafenib had prolonged efficacy in patients with BRAF V600-mutant ECD and LCH and warrants consideration as a new standard of care for these patients.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1001/jamaoncol.2017.5029

  3 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29214791
[Au] Autor:Ahn MJ; Yu JE; Jeong J; Sim DW; Koh YI
[Ad] Address:Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
[Ti] Title:A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra.
[So] Source:Yonsei Med J;59(1):154-157, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:Chronic urticaria may often be associated with interleukin (IL)-1-mediated autoinflammatory disease, which should be suspected if systemic inflammation signs are present. Here, we report a case of Schnitzler's syndrome without monoclonal gammopathy treated successfully with the IL-1 receptor antagonist anakinra. A 69-year-old man suffered from a pruritic urticarial rash for 12 years. It became aggravated episodically and was accompanied by high fever, arthralgia, leukocytosis, and an elevated C-reactive protein and erythrocyte sedimentation rate. The episodes each lasted for over one week. Neutrophilic and eosinophilic inflammation was found on skin biopsy. However, serum and urine electrophoresis showed no evidence of monoclonal gammopathy. The cutaneous lesions were unresponsive to various kinds of anti-histamines, systemic glucocorticoids, colchicine, cyclosporine, dapsone, and methotrexate, which were administered over a span of 3 years immediately preceding successful treatment. A dramatic response, however, was observed after a daily administration of anakinra. This observation suggests that the correct diagnosis of this case is Schnitzler's syndrome without monoclonal gammopathy. For an adult patient with refractory chronic urticaria and systemic inflammation, Schnitzler's syndrome could be considered as a possible differential diagnosis. Although the typical form of Schnitzler's syndrome exhibits the presence of monoclonal gammopathy as a diagnostic criterion, monoclonal gammopathy may be absent in an atypical form. In such a situation, an IL-1 antagonist should be effective for the management of chronic urticaria.
[Mh] MeSH terms primary: Interleukin 1 Receptor Antagonist Protein/therapeutic use
Paraproteinemias/complications
Schnitzler Syndrome/drug therapy
Urticaria/complications
[Mh] MeSH terms secundary: Aged
Blood Sedimentation
C-Reactive Protein/metabolism
Chronic Disease
Humans
Leukocytes/metabolism
Male
Schnitzler Syndrome/blood
[Pt] Publication type:CASE REPORTS
[Nm] Name of substance:0 (Interleukin 1 Receptor Antagonist Protein); 9007-41-4 (C-Reactive Protein)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.154

  4 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518067
[Au] Autor:Hall V; Walker WL; Lindsey NP; Lehman JA; Kolsin J; Landry K; Rabe IB; Hills SL; Fischer M; Staples JE; Gould CV; Martin SW
[Ti] Title:Update: Noncongenital Zika Virus Disease Cases - 50 U.S. States and the District of Columbia, 2016.
[So] Source:MMWR Morb Mortal Wkly Rep;67(9):265-269, 2018 Mar 09.
[Is] ISSN:1545-861X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Zika virus is a flavivirus primarily transmitted to humans by Aedes aegypti mosquitoes (1). Zika virus infections also have been documented through intrauterine transmission resulting in congenital infection; intrapartum transmission from a viremic mother to her newborn; sexual transmission; blood transfusion; and laboratory exposure (1-3). Most Zika virus infections are asymptomatic or result in mild clinical illness, characterized by acute onset of fever, maculopapular rash, arthralgia, or nonpurulent conjunctivitis; Guillain-Barré syndrome, meningoencephalitis, and severe thrombocytopenia rarely have been associated with Zika virus infection (1). However, congenital Zika virus infection can result in fetal loss, microcephaly, and other birth defects (1,2). In 2016, a total of 5,168 noncongenital Zika virus disease cases were reported from U.S. states and the District of Columbia. Most cases (4,897, 95%) were in travelers returning from Zika virus-affected areas. A total of 224 (4%) cases were acquired through presumed local mosquitoborne transmission, and 47 (1%) were acquired by other routes. It is important that providers in the United States continue to test symptomatic patients who live in or recently traveled to areas with ongoing Zika virus transmission or had unprotected sex with someone who lives in or traveled to those areas. All pregnant women and their partners should take measures to prevent Zika virus infection during pregnancy. A list of affected areas and specific recommendations on how to prevent Zika virus infection during pregnancy are available at https://www.cdc.gov/pregnancy/zika/protect-yourself.html.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.15585/mmwr.mm6709a1

  5 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516410
[Au] Autor:Louis EJ; Reinisch W; Schwartz DA; Löfberg R; Robinson AM; Berg S; Wang AW; Maa JF; Huang B; Pappalardo B
[Ad] Address:University Hospital CHU of Liège, Liège, Belgium. edouard.louis@ulg.ac.be.
[Ti] Title:Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.
[So] Source:Adv Ther;, 2018 Mar 07.
[Is] ISSN:1865-8652
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Extraintestinal manifestations (EIMs) in patients with Crohn's disease (CD) are common and associated with additional morbidity. This study aimed to evaluate the effect of adalimumab therapy on EIM resolution and identify potential predictors of EIM resolution in adult and pediatric patients with moderate to severe CD. METHODS: EIM data were pooled from 11 induction, maintenance, and open-label extension studies of adalimumab. Resolution of EIMs was evaluated at approximately 6 months and 1 year. Median time to initial EIM resolution and first EIM recurrence (reflecting durable resolution) of any EIM and specific categories of EIMs (arthritis/arthralgia, ocular, cutaneous) were calculated. A Cox model was used to determine predictors of initial and durable EIM resolution. RESULTS: At baseline, 54% (1137/2094) of patients receiving adalimumab and 51% (297/586) receiving placebo had EIMs. EIM resolution occurred in a significantly greater proportion of adalimumab versus placebo patients at 6 months (54% vs 31%; P < .001) and 1 year (60% vs 42%; P = .008). Median time to initial resolution of any EIM, arthritis/arthralgia, and cutaneous EIMs was significantly shorter in patients receiving adalimumab versus placebo. Durable resolution of any EIM and arthritis/arthralgia was significantly longer for patients receiving adalimumab versus placebo. Clinically meaningful predictors of EIM resolution included adalimumab treatment, male sex, and moderate (versus severe) disease activity at baseline. CONCLUSION: Adalimumab is effective for achieving initial and durable resolution of any EIM and, in particular, arthritis/arthralgia in patients with moderate to severe CD. Predictors of EIM resolution included adalimumab treatment and moderate disease severity. FUNDING: AbbVie.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1007/s12325-018-0678-0

  6 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29515068
[Au] Autor:Kubota H; Saida S; Kouzuki K; Hamabata T; Daifu T; Kato I; Umeda K; Hiramatsu H; Nishikomori R; Heike T; Okamoto T; Adachi S
[Ad] Address:Department of Pediatrics, Graduate School of Medicine, Kyoto University.
[Ti] Title:[Pediatric acute lymphoblastic leukemia presenting with bone and joint pain].
[So] Source:Rinsho Ketsueki;59(2):167-173, 2018.
[Is] ISSN:0485-1439
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:We report on three cases of pediatric acute lymphoblastic leukemia presenting with bone pain and arthralgia as initial symptoms. At the first visit, their primary signs were recurrent bone pain and arthralgia, without significant peripheral blood abnormalities. It took 2-4 months to confirm the diagnosis from the onset of arthralgia due to this atypical presentation of the disease. Definitive diagnosis was obtained by bone marrow examination, and in all cases, complete remission was achieved by chemotherapy. As a feature of imaging, MRI exhibited diffuse bone marrow signal changes in T1-weighted images, and FDG-PET showed extensive abnormal bone marrow uptakes. In cases 2 and 3, it was difficult to diagnose by bone marrow aspiration from the iliac bone, but definitive diagnosis was obtained by bone marrow aspiration from the tibia, in which FDG-PET showed increased uptake. FDG-PET was therefore considered useful for the selection of bone marrow aspiration sites. In cases presenting with recurrent migratory bone pain and arthralgia, we need to consider performing bone marrow aspiration and imaging, such as MRI and FDG-PET, for early diagnosis and treatment of leukemia.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.11406/rinketsu.59.167

  7 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29216376
[Au] Autor:Lozier MJ; Burke RM; Lopez J; Acevedo V; Amador M; Read JS; Jara A; Waterman SH; Barrera R; Muñoz-Jordan J; Garcia-Rivera B; Sharp TM
[Ad] Address:National Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention, Puerto Rico.
[Ti] Title:Differences in prevalence of symptomatic Zika virus infection by age and sex-Puerto Rico, 2016.
[So] Source:J Infect Dis;, 2017 Dec 06.
[Is] ISSN:1537-6613
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: During the Zika virus (ZIKV) outbreak in Puerto Rico in 2016, non-pregnant women aged 20-39 years were disproportionately identified with ZIKV disease. We used household-based cluster investigations to determine if this disparity was associated with age- or sex-dependent differences in the rate of ZIKV infection or reporting symptoms. Methods: Participation was offered to residents of households within a 100-meter radius of the residences of a convenience sample of 19 laboratory-confirmed ZIKV disease cases. Participants answered a questionnaire and provided specimens for diagnostic testing by RT-PCR and ELISA. Results: Among 367 study participants, 114 (31.1%) were laboratory-positive for ZIKV infection, of which 30% reported a recent illness (defined as self-reported rash or arthralgia) attributable to ZIKV infection. Age and sex were not associated with ZIKV infection. Female sex (adjusted prevalence ratio [aPR]=2.28; 95% confidence interval [CI]=1.40, 3.67), age <40 years (aPR=2.39; 95% CI=1.55, 3.70), and asthma (aPR=1.63; 95% CI=1.12, 2.37) were independently associated with symptomatic infection. Conclusions: Although neither female sex nor age were associated with increased prevalence of ZIKV infection, both were associated with symptomatic infection. Further investigation to identify a potential mechanism of age- and sex-dependent differences in reporting symptomatic ZIKV infection is warranted.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/infdis/jix630

  8 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29512949
[Au] Autor:Zambaz C; Dan D
[Ad] Address:Service de rhumatologie, Département de l'appareil locomoteur, CHUV, 1011 Lausanne.
[Ti] Title:Arthrites virales. [Viral arthritis].
[So] Source:Rev Med Suisse;14(597):526-528, 2018 Mar 07.
[Is] ISSN:1660-9379
[Cp] Country of publication:Switzerland
[La] Language:fre
[Ab] Abstract:Arthritis and arthralgia during a viral infection are often polyarticular and symmetric and can mimic rheumatoid arthritis. Depending on germs, others signs and symptoms as fever, cutaneous rash (Parvovirus B19) or jaundice (hepatitis) can be present. Worldwide most common germs are Parvovirus B19, hepatitis B and C, HIV and alphavirus. There are significant differences throughout the world and epidemiology continues to evolve with a progression of vector-borne infections. Diagnosis of viral arthritis is often difficult and is based on epidemiological, clinical and serological data.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review

  9 / 11447 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29490685
[Au] Autor:Zerkaoui M; Laarabi FZ; Ajhoun Y; Chkirate B; Sefiani A
[Ad] Address:Human Genomic Centre, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco. maria.zerkaoui@gmail.com.
[Ti] Title:A novel single variant in the MEFV gene causing Mediterranean fever and Behçet's disease: a case report.
[So] Source:J Med Case Rep;12(1):53, 2018 Mar 01.
[Is] ISSN:1752-1947
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Familial Mediterranean fever is an autoinflammatory disease of unknown etiology, characterized clinically by recurrent attacks of sudden-onset fever with arthralgia and/or thoracoabdominal pain and pathogenetically by autosomal recessive inheritance due to a mutation in the MEFV gene. Behçet's disease is an inflammatory disease characterized by recurrent oral and genital aphthous ulcerations, uveitis, and skin lesions. Preliminarily, our literature review suggested that patients with familial Mediterranean fever who also have Behçet's disease have only a single mutated familial Mediterranean fever gene. The MEFV gene mutation responsible for familial Mediterranean fever is probably a susceptibility factor for Behçet's disease, particularly for patients with vascular involvement, and both disorders can occur concurrently in a patient, as in the present case. CASE PRESENTATION: A 10-year-old girl of Moroccan origin presented to our institution for genetic consultation for genetic testing of the MEFV gene. She had fever associated with abdominal and diffuse joint pain in addition to headache. These symptoms have oriented pediatricians to familial Mediterranean fever. The evolution was marked by Behçet's syndrome symptoms. Sanger sequencing followed by complete exome sequencing analysis of the MEFV gene for the proband mutation revealed a novel variant. We conclude that the novel single variant c.2078 T > A (p.Met693Lys) could be responsible for the association of familial Mediterranean fever and Behçet's disease. CONCLUSION: To the best of our knowledge, this is the first report of a new variant in exon 10 of the MEFV gene in a Moroccan family. This novel variant should be listed in the MEFV sequence variant databases.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.1186/s13256-017-1552-4

  10 / 11447 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29486726
[Au] Autor:Ehelepola NDB; Rajapaksha RKGM; Dhanapala DMUB; Thennekoon TDK; Ponnamperuma S
[Ad] Address:The Teaching (General) Hospital - Kandy, Kandy, Sri Lanka. drehelepola@gmail.com.
[Ti] Title:Concurrent methicillin-resistant Staphylococcus aureus septicemia and pyomyositis in a patient with dengue hemorrhagic fever: a case report.
[So] Source:BMC Infect Dis;18(1):99, 2018 Feb 27.
[Is] ISSN:1471-2334
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Concurrent presence of dengue hemorrhagic fever (DHF), tropical pyomyositis and septicemia due to methicillin-resistant Staphylococcus aureus (MRSA) in a previously healthy person has never been reported. These three conditions even individually are potentially fatal. "Here we describe a case of a patient contracting dengue and developing DHF along with concurrent pyomyositis likely to be due to MRSA, leading to MRSA septicemia with abscesses formed by MRSA". CASE PRESENTATION: A 44-year old previously healthy Sinhalese man presented on day 3 of the illness with fever, headache, arthralgia and myalgia and watery loose stools. His pulse rate was 76/min, blood pressure was 110/80 mmHg, while cardiovascular, respiratory and abdomen examination findings were unremarkable. The test for the dengue NS1 antigen was positive on the same day. We have diagnosed dengue and started managing him symptomatically as per the current national guidelines. The patient developed DHF with bilateral pleural effusion and ascitis. On the day 5 he developed severe myalgia, tenderness and non pitting edema of lower limbs especially in the thighs. His creatine kinase levels were high and an ultrasound scan confirmed myositis of both thighs. We suspected myositis due to dengue but investigated for possible simultaneous sepsis as well. On day 9 his blood culture became positive for MRSA. Considering the sensitivity of the bacteria intravenous vancomycin and ciprofloxacin was administered for 21 days. He developed a small abscess at the site of the first intravenous access and a large one above the ankle on the left. On day 12 the latter was drained and the pus culture yielded MRSA sensitive to the same antibiotics. The rapid test for dengue IgM was negative initially but later a positive MAC-ELISA test entrenched dengue infection. After improvement he was sent home on day 33 of the illness. He has developed two other abscesses in the proximity of the drained one and they were drained on day 57. The patient recovered. CONCLUSIONS: When dengue patients develop symptoms and signs of myositis, prompt investigations for pyomyositis and the treatment can save lives.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1186/s12879-018-3012-1


page 1 of 1145 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information